Can oliceridine (TRV130), an ideal novel μ receptor G protein pathway selective (μ-GPS) modulator, provide analgesia without opioid-related adverse reactions?
3
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
All drugs have both favorable therapeutic and untoward adverse effects. Conventional opioid analgesics possess both analgesia and adverse reactions, such as nausea, vomiting, and respiratory depression. The opioid ligand binds to μ opioid receptor and non-selectively activates two intracellular signaling pathways: the G protein pathway induce analgesia, while the β-arrestin pathway is responsible for the opioid-related adverse reactions. An ideal opioid should activate the G protein pathway while deactivating the β-arrestin pathway. Oliceridine (TRV130) has a novel characteristic mechanism on the action of the β receptor G protein pathway selective (μ-GPS) modulation. Even though adverse reactions (ADRs) are significantly attenuated, while the analgesic effect is augmented, the some residual ADRs persist. Consequently, a G protein biased μ opioid ligand, oliceridine, improves the therapeutic index owing to increased analgesia with decreased adverse events. This review article provides a brief history, mechanism of action, pharmacokinetics, pharmacodynamics, and ADRs of oliceridine. (Korean J Pain 2018; 31: 73-9)
Abstract
All drugs have both favorable therapeutic and untoward adverse effects. Conventional opioid analgesics possess both analgesia and adverse reactions, such as nausea, vomiting, and respiratory depression. The opioid ligand binds to μ opioid receptor and non-selectively activates two intracellular signaling pathways: the G protein pathway induce analgesia, while the β-arrestin pathway is responsible for the opioid-related adverse reactions. An ideal opioid should activate the G protein pathway while deactivating the β-arrestin pathway. Oliceridine (TRV130) has a novel characteristic mechanism on the action of the β receptor G protein pathway selective (μ-GPS) modulation. Even though adverse reactions (ADRs) are significantly attenuated, while the analgesic effect is augmented, the some residual ADRs persist. Consequently, a G protein biased μ opioid ligand, oliceridine, improves the therapeutic index owing to increased analgesia with decreased adverse events. This review article provides a brief history, mechanism of action, pharmacokinetics, pharmacodynamics, and ADRs of oliceridine. (Korean J Pain 2018; 31: 73-9)
참고문헌 (34)
- ethyl})amine (TRV130), for the treatment of acute severe pain, "J Med Chem", 2013, 8019~8031, 10.1021[DOI]
- Williams JT, "Regulation of <TEX>${\mu}$<", TEX>-opioid receptors: desensitization, phosphorylation, internalization, and tolerance, 2013, pp.65, 223~254
- Fredriksson R, "The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints", Mol Pharmacol, 63, pp.1256~1272 (2003)[DOI]
- Kochman K, "Superfamily of G-protein coupled receptors (GPCRs)--extraordinary and outstanding success of evolution", Postepy Hig Med Dosw (Online), 68, pp.1225~1237 (2014)[DOI]
- Schioth HB, "The GRAFS classification system of G-protein coupled receptors in comparative perspective", Gen Comp Endocrinol, 142, pp.94~101 (2005)[DOI]
- Smith HS, "Peripherally-acting opioids", Pain Physician, 11, pp.121~132 (2008)
- Sehgal N, "Peripherally acting opioids and clinical implications for pain control", Pain Physician, 14, pp.249~258 (2011)
- Burness CB, "Oxycodone", naloxone prolongedrelease: a review of its use in the management of chronic pain while counteracting opioid-induced constipation, 2014, pp.74, 353~375
- Morlion B, "Quality of life and healthcare resource in patients receiving opioids for chronic pain: a review of the place of oxycodone", naloxone, 2015, pp.35, 1~11
- Violin JD, "Biased ligands at G-protein-coupled receptors: promise and progress", Trends Pharmacol Sci, 35, pp.308~316 (2014)[DOI]
- Bohn LM, "Enhanced morphine analgesia in mice lacking beta-arrestin 2", Science, 286, pp.2495~2498 (1999)
- Bohn LM, "Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence", Nature, 408, pp.720~723 (2000)[DOI]
- Raehal KM, "Morphine side effects in beta-arrestin 2 knockout mice", J Pharmacol Exp Ther, 314, pp.1195~1201 (2005)
- Soergel DG, "First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers", J Clin Pharmacol, 54, pp.351~357 (2014)[DOI]
- Soergel DG, "Biased agonism of the <TEX>${\mu}$<", TEX>-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, doubleblind, placebo-controlled, crossover study in healthy volunteers, 2014, pp.155, 1829~1835
- Fossler M, "Oliceridine (TRV130), a novel <TEX>${\mu}$<", TEX> receptor G protein pathway selective modulator (<TEX>${\mu}$<, pharmacodynamic (PK, pp.PD) model, J Pain[DOI]
- Fossler M, "(343) Oliceridine (TRV130), a novel <TEX>${\mu}$<", TEX> receptor G protein pathway selective modulator (<TEX>${\mu}$<, pharmacodynamic (PK, pp.PD) model, J Pain[DOI]
- Viscusi E, "(433) Rapid reduction in pain intensity with oliceridine (TRV130), a novel <TEX>${\mu}$<", TEX> receptor G protein pathway selective modulator (<TEX>${\mu}$<, J Pain, pp.2016, 17[DOI]
- Singla N, "(432) Respiratory safety signal with oliceridine (TRV130), a novel <TEX>${\mu}$<", TEX> receptor G protein pathway selective modulator (<TEX>${\mu}$<, J Pain, pp.2016, 17[DOI]
- Minkowitz H, "(435) Nausea and vomiting with oliceridine (TRV130), a novel <TEX>${\mu}$<", TEX> receptor G protein pathway selective modulator (<TEX>${\mu}$<, J Pain, pp.2016, 17[DOI]
- Viscusi ER, "A randomized, phase 2 study investigating TRV130, a biased ligand of the <TEX>${\mu}$<", TEX>-opioid receptor, for the intravenous treatment of acute pain, 2016, pp.157, 264~272
- Madariaga-Mazon A, "Mu-Opioid receptor biased ligands: a safer and painless discovery of analgesics?", Drug Discov Today, 22, pp.1719~1729 (2017)[DOI]
- Pierce KL, "Seven-transmembrane receptors", Nat Rev Mol Cell Biol, 3, pp.639~650 (2002)[DOI]
- Jacoby E, "The 7 TM G-protein-coupled receptor target family", ChemMedChem, 1, pp.760~782 (2006)[DOI]
- McCudden CR, "G-protein signaling: back to the future", Cell Mol Life Sci, 62, pp.551~577 (2005)[DOI]
- Patel TB, "Single transmembrane spanning heterotrimeric G protein-coupled receptors and their signaling cascades", Pharmacol Rev, 56, pp.371~385 (2004)[DOI]
- Whalen EJ, "Therapeutic potential of <TEX>${\beta}$<", TEX>-arrestin- and G protein-biased agonists, 2011, pp.17, 126~139
- Kliewer A, "Emerging paradigms of G protein-coupled receptor dephosphorylation", Trends Pharmacol Sci, 38, pp.621~636 (2017)[DOI]
- Dang VC, "Mechanisms of rapid opioid receptor desensitization, resensitization and tolerance in brain neurons", Br J Pharmacol, 165, pp.1704~1716 (2012)[DOI]
- Allouche S, "Opioid receptor desensitization: mechanisms and its link to tolerance", Front Pharmacol, 5, pp.280~ (2014)
- Wright JM, "The double-edged sword of COX-2 selective NSAIDs", CMAJ, 167, pp.1131~1137 (2002)
- Del Vecchio G, "Novel opioid analgesics and side effects", ACS Chem Neurosci, 8, pp.1638~1640 (2017)[DOI]
- Manglik A, "Structure-based discovery of opioid analgesics with reduced side effects", Nature, 537, pp.185~190 (2016)
- Siuda ER, "Biased mu-opioid receptor ligands: a promising new generation of pain therapeutics", Curr Opin Pharmacol, 32, pp.77~84 (2017)